Yap1 Mediates Trametinib Resistance in Head and Neck Squamous Cell Carcinomas

PURPOSE: In a head and neck squamous cell carcinoma (HNSCC) “window of opportunity” clinical trial, we reported that trametinib reduced MEK-Erk1/2 activation and resulted in tumor responses in a subset of patients. Here, we investigated resistance to trametinib and molecular correlates in HNSCC cell...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Clin Cancer Res
Main Authors: Mudianto, Tenny, Campbell, Katie M., Webb, Jason, Zolkind, Paul, Skidmore, Zachary L., Riley, Rachel, Barnell, Erica K., Ozgenc, Ibrahim, Giri, Tusar, Dunn, Gavin P., Adkins, Douglas R., Griffith, Malachi, Egloff, Ann Marie, Griffith, Obi L, Uppaluri, Ravindra
Format: Artigo
Jezik:Inglês
Izdano: 2021
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC8046740/
https://ncbi.nlm.nih.gov/pubmed/33547198
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-19-4179
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki